Key Developments For Rosetta Genomics Ltd.
Rosetta Genomics Ltd. (ROSG.O) (Consolidated Issue listed on NASDAQ Global Market)
USPTO Issues Patent To Rosetta Genomics Ltd.
Rosetta Genomics Ltd. announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,592,441 to Rosetta Genomics. The patent relates to human microRNA miR-193b, as well as to complementary probes and vectors. In addition to the three issued patents, Rosetta Genomics has received eight Notices of Allowance from the USPTO for patent applications related to human Sanger microRNAs 18b, 20b, 92b, 494, 135b, 527, 196b and 491.
Rosetta Genomics Ltd. Names Kenneth A. Berlin President And Chief Executive Officer
Rosetta Genomics Ltd. announced the appointment of Kenneth A. Berlin to the position of President and Chief Executive Officer, effective November 2, 2009. Rosetta Genomics` Board of Directors has recommended that Mr. Berlin also be appointed to serve on the Rosetta Genomics` Board of Directors.
Rosetta Genomics Ltd. And Warnex Inc.'s Warnex Medical Laboratories Announce Exclusive Distribution Agreement
Rosetta Genomics Ltd. and Warnex Medical Laboratories, a division of Warnex Inc. announced that they have signed an exclusive distribution agreement in Canada for three currently-available diagnostic tests. Under the terms of the agreement, Warnex will market Rosetta Genomics` miRview tests. Samples will be sent from Canada to Rosetta Genomics` Philadelphia-based CLIA-certified laboratory for analysis. The terms of the deal were not disclosed.
Rosetta Genomics Ltd. Announces Closing of License And Collaboration Agreement
Rosetta Genomics Ltd. announced the closing of its previously announced license and collaboration transaction with Prometheus Laboratories Inc., pursuant to which Rosetta has granted Prometheus U.S. rights to three recently introduced, microRNA based cancer diagnostic tests: miRview mets, miRview squamous and miRview meso. In conjunction with the closing of the licensing transaction, the parties also closed the previously announced purchase of 2,000,000 Rosetta ordinary shares by Prometheus at $4.00 per share.
Prometheus Laboratories Inc. And Rosetta Genomics Ltd. Announces License And Collaboration Agreement
Prometheus Laboratories Inc. and Rosetta Genomics Ltd announced the execution of a license and collaboration agreement under which Rosetta shall grant Prometheus U.S. rights to three recently introduced, microRNA-based cancer diagnostic tests: miRview mets, miRview squamous and miRview meso. The terms of the license agreement provide for payments to Rosetta, either as milestones or research and development funding, as well as royalty payments on net sales in the U.S. Under the terms of a separate stock purchase agreement, Prometheus will also make an equity investment in Rosetta of $8 million at $4.00 per ordinary share, representing an approximate 41% premium over the closing price of Rosetta stock over three business days. The license and collaboration agreement and the stock purchase agreement are expected to close before the end of April 2009 and are subject to customary closing conditions. In addition, Prometheus and Rosetta have agreed to collaborate to develop two new microRNA-based gastroenterology tests, which may result in additional, success-based milestones and royalty payments to Rosetta. Funding for development of these gastroenterology tests will be provided by Prometheus.
